Taro Pharmaceutical Industries Limited

Taro Pharmaceuticals Industries

Taro Pharmaceuticals U.s.a., Inc.

Taro Pharmaceuticals Inc.

Taro Vit Industries, Ltd.

Taro Pharamaceutical Industries Ltd.

Barrie Levitt

Daniel A Moros

Avraham Yacobi

Morris Stolar

Michael M Friedman

Daniella Gutman

Howard Rutman

Yechiel Golander

Ron Breiman

Dan Moros

Maya Barder

Mohammed S Safadi

Daniela Licht

Abraham Yacobi

Marina Zholkoysky

Roman Kaplan

Methods of providing neuroprotection are disclosed comprising administering a non-sedative barbiturate compound in an amount sufficient to achieve neuroprotection in a mammalian subject. Preferred compounds are in the family of diphenylbarbituric acid and analogs. Preferred doses for a neuroprotective effect exceed the dosage of a corresponding sedative barbiturate without sedative side-effects such as anesthesia and death.

Non-sedating barbiturate compounds as neuroprotective agents

The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.

Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Methods of providing neuroprotection are disclosed comprising administering a non-sedative barbiturate compound in an amount sufficient to achieve neuroprotection in a mammalian subject. Preferred compounds are in the family of diphenylbarbituric acid and analogs. Preferred doses for a neuroprotective effect exceed the dosage of a corresponding sedative barbiturate without sedative side-effects such as anesthesia and death

The invention is directed to non-hygroscopic oral pharmaceutical compositions of a salt of valproic acid, and processes for preparing the compositions. The non-hygroscopic pharmaceutical compositions are prepared by blending a hygroscopic salt of valproic acid, carbomer, and a non-hygroscopic additive.

Process for preparing non-hygroscopic sodium valproate composition

The present invention provides a pharmaceutical preparation in tablet form, where the active ingredient is an anti-epileptic medication, preferably a sustained release formulation, and most preferably a sustained release formulation where the active ingredient is carbamazepine. The product consists of carbamazepine particles coated with a single hydrophobic layer and is in a disintegrating tablet form.

Sustained release formulation of carbamazepine

New 2-alkyl-3-(4-hydroxy-3,5-di-tert-butylbenzoyl)benzofurans useful for treating cardiac arrhythmia, as well as pharmaceutical compositions containing these benzofurans and the method of treating cardiac arrhythmia therewith are disclosed.

2-alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia

New 2-alkyl-3-[4-(omega-N,N-dialkylaminoacylamino)-3,5-dialkylbenzoyl]benzofur ans useful for treating cardiac arrhythmia, as well as pharmaceutical compositions containing these benzofurans and the method of treating cardiac arrhythmia therewith are disclosed.

2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia

There are disclosed novel oxopyrimidine derivatives of the general formula ##STR1## wherein R.sub.1 and R.sub.2 may be the same or different and are each hydrogen or lower alkyl optionally substituted by lower alkoxy, and R.sub.3 and R.sub.4 may be the same or different and are each phenyl optionally substituted by lower alkyl or halogen, provided that when R.sub.1 and R.sub.2 are both hydrogen, R.sub.3 and R.sub.4 are each substituted phenyl. Pharmaceutical compositions containing these compounds and their use as anticonvulsant, antianxiety and muscle relaxant agents are described.

Growing community of inventors

Mamaroneck, NY, United States of America

Barrie Levitt